Rules

You are here

DOT Rule 49 CFR Part 40 Section 40.87

Subpart F - Drug Testing Laboratories

§ 40.87  What are the cutoff concentrations for drug tests?
 
(a) As a laboratory, you must use the cutoff concentrations displayed in the following table for initial and confirmatory drug tests. All cutoff concentrations are expressed in nanograms per milliliter (ng/mL). 
 
Initial test analyteInitial test cutoff concentrationConfirmatory test analyteConfirmatory test cutoff concentration
Marijuana metabolites50 ng/mLTHCA115 ng/mL
Cocaine metabolites150 ng/mLBenzoylecgonine100  ng/mL
Opiate metabolites   
Codeine/Morphine22000 ng/mLCodeine2000 ng/mL
  Morphine2000 ng/mL
6-Acetylmorphine10 ng/mL6-Acetylmorphine10 ng/mL
Phencyclidine25 ng/mLPhencyclidine25 ng/mL
Amphetamines3   
AMP/MAMP4500 ng/mLAmphetamine250 ng/mL
  Methamphetamine5250 ng/mL
MDMA6   
  500 ng/mLMDMA250 ng/mL
    MDA7250 ng/mL
    MDEA8250 ng/mL
 
1Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA).
2Morphine is the target analyte for codeine/morphine testing.
3Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
4Methamphetamine is the target analyte for amphetamine/methamphetamine testing.
5To be reported positive for methamphetamine, a specimen must also contain amphetamine at a concentration equal to or greater than 100 ng/mL.
6Methylenedioxymethamphetamine (MDMA).
7Methylenedioxyamphetamine (MDA).
8Methylenedioxyethylamphetamine (MDEA).
 
(b) On an initial drug test, you must report a result below the cutoff concentration as negative. If the result is at or above the cutoff concentration, you must conduct a confirmation test.
 
(c) On a confirmation drug test, you must report a result below the cutoff concentration as negative and a result at or above the cutoff concentration as confirmed positive.
 
(d) You must report quantitative values for morphine or codeine at 15,000 ng/mL or above.
 
[65 FR 79526, Dec. 19, 2000, as amended at 75 FR 49862, August 16, 2010; 77 FR 26473, May 4, 2012]
Updated: Wednesday, January 16, 2013